問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳靖博
下載
2021-02-25 - 2024-06-05
Condition/Disease
Test Drug
Participate Sites9Sites
Recruiting9Sites
2021-08-31 - 2026-12-31
Participate Sites18Sites
Not yet recruiting9Sites
2022-12-31 - 2024-01-04
Participate Sites5Sites
Recruiting5Sites
2025-06-13 - 2030-06-30
Primary Membranous Nephropathy (PMN)
powder
Participate Sites10Sites
Recruiting10Sites
2022-08-01 - 2029-06-04
2022-05-02 - 2026-09-30
Participate Sites6Sites
Recruiting6Sites
2021-02-01 - 2025-12-31
2022-01-05 - 2029-11-11
xxxxxx
Sibeprenlimab (VIS649) Sibeprenlimab (VIS649)
2019-06-15 - 2023-09-14
IgA Nephropathy
Cemdisiran (ALN-CC5)
全部
